Research Triangle Park, North Carolina-based G1 Therapeutics, a clinical-stage oncology company, has recruited Stillman Hanson to the newly created position of general counsel.
Hanson most recently served as associate general counsel and vice president at IQVIA, where he led the Quintiles legal team in the $20 billion merger of Quintiles and IMS Health to create QuintilesIMS, now IQVIA, according to G1.
In previous positions at Quintiles, Hanson negotiated strategic contracts, represented Quintiles in its IPO and was responsible for its public company securities reporting. Before joining Quintiles in 2010, he practiced corporate law, including M&A, commercial contracting, securities reporting and corporate governance.
G1 has also hired John Demaree as chief commercial officer – another newly created role at the company. Demaree previously served as vice president for oncology marketing at Astellas Pharma.
‘We are excited to welcome John and Stillman to G1, and look forward to their contributions as we build out our commercial capabilities and expand our business development, legal and regulatory efforts,’ says CEO Mark Velleca in a statement. ‘John’s experience building a world-class commercial oncology organization will be invaluable as our three clinical-stage programs move toward key clinical and regulatory milestones.
‘Moreover, Stillman’s extensive life sciences corporate legal experience will be critical as the company continues to grow and evolve from research and development to commercialization.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
